HT
Halozyme Therapeutics Inc.
HALO· Health Care· BiotechnologyS&P 400
Close · 13/11/2026
100.27
1D
-0.40%52-week range
61.23 – 134
Volume
22,76,300.00
Price history
HALO
15/10/2026 to 13/11/2026
O 100.32 H 101.23 L 99.26
1W-3.24%
1M-17.48%
3M-2.65%
6M+49.39%
1Y+41.97%
3Y+172.84%
5Y+146.30%
MAX+144.68%
Fundamentals
as of 13/11/2026- Market cap
- $11.43B
- Shares out
- 114.01M
- P/E (trailing)
- 23.55
- P/E (forward)
- 9.47
- EPS (trailing)
- 4.26
- Dividend yield
- 0.00%
- Beta
- 0.90
- Profit margin
- 26.93%
- P/B
- -206.74
- Return on equity
- 216.38%
SEC financial statements
60 quarterly and 17 annual periods through 30/09/2026.
Details
- Ticker
- HALO
- Index
- SP400
- Sector
- Health Care
- Industry
- Biotechnology
- HQ
- -
Last close 13/11/2026.
Tracked by Congress
3 filers · 1 on watchlist · 1 buy · 6 sells · ?: 1 · D: 6
- 29/09/2026Gilbert CisnerosSell+Halozyme Therapeutics, Inc. - Common Stock$1,001–$15,000
- 09/03/2026Gilbert CisnerosBuyHalozyme Therapeutics, Inc. - Common Stock$1,001–$15,000
- 24/03/2025Gilbert CisnerosSell+Halozyme Therapeutics, Inc. - Common Stock$1,001–$15,000
- 09/09/2024Josh GottheimerWSell+Halozyme Therapeutics, Inc. - Common Stock$1,001–$15,000
- 12/07/2023Daniel GoldmanSellHalozyme Therapeutics, Inc.$15,001–$50,000
- 06/12/2022Josh GottheimerWSell+Halozyme Therapeutics, Inc.$1,001–$15,000
- 05/08/2022Josh GottheimerWSell+Halozyme Therapeutics, Inc.$1,001–$15,000